Pediatric Patch Test Protocol: What the Study Must Prove

A pediatric patch test protocol is a dated document, not a certificate. It fixes 6 fields before a single patch touches skin. Those fields are the subject criteria, the dose, the site, the occlusion window, the reading days and the pass mark. No market publishes a separate pediatric patch test standard. Buyers still ask for one, because the claim sits on children's skin.

DEVA Skincare has made baby and sensitive skin products for 20 years. Claim work starts at the brief. Our bench carries 150 efficacy and safety protocols. Every pediatric patch test protocol we hand a brand names its age band, its reading schedule and its pass mark.

What Is a Pediatric Patch Test Protocol?

A pediatric patch test protocol fixes 6 fields, and each one changes the result. Set the dose too high and the panel reacts to the load, not the formula. Read the site too early and a delayed reaction never shows up.

The word pediatric adds 3 constraints to the general patch test method. The age band comes from ICH E11(R1), adopted in July 2017. Ethics limits who may join the panel, and China writes its own pass mark for children's products.

The claim gets no help from the wording. The EU Technical Document on Cosmetic Claims reads "dermatologically tested" as a product tested on humans under a dermatologist's supervision. It also lists 8 fields the report has to carry. No regulator defines "pediatric dermatologist tested". The study behind the claim does the work.

Field in a pediatric patch test protocol	What it must state	What goes wrong when it is missing
Subject band	A named ICH E11(R1) band	Wrong age group on the label
Dose and chamber	0.020 to 0.025 g or mL, or 20 mg in an 8 mm chamber	Rim overflow reads as irritation
Site	Upper back, chambers 15 mm apart	Two wells blur into one reading
Occlusion window	24 hours for a claim file, 48 for a diagnostic series	Contact time sets penetration
Reading days	30 minutes, 24 hours, 48 hours, day 3 or 4, day 7	A late reaction files as negative
Pass mark	The count rule of the target market	The dossier fails at the border

Why Can You Not Patch Test Infants Directly?

The panel holds 0 children, and that is a regulatory position rather than a preference. China's Children's Cosmetics Technical Guidance Principles give the reason in one line. Clinical trials cannot be conducted on children.

That document is NMPA Institute for Food and Drug Control Notice No. 1 of 2023, issued on 31 August 2023 and effective the same day. It asks for efficacy evidence from Chinese adult consumers instead, plus post-market adverse reaction data from Chinese child consumers.

In the EU, Article 2(2) of Regulation (EU) No 536/2014 puts a skin compatibility study on a finished cosmetic outside the clinical trial framework. No ethics committee approval is needed. The Declaration of Helsinki still applies, with written informed consent and adverse event reporting.

Children do get patch tested in clinics, but under a different rule. A 2009 review in Der Hautarzt found that the same allergen preparations and technique used on adults work on children, with a shortened series and small Finn chambers worn for 1 day. That is a diagnosis for a child with persistent eczema, not claim substantiation. No buyer can cite it as one.

The SCCS Notes of Guidance holds that human testing cannot identify a sensitisation hazard on its own. So the pediatric patch test protocol screens in chemico and in vitro first, then confirms on an adult panel.

Which Tests Belong in a Pediatric Patch Test Protocol?

A full pediatric patch test protocol stacks 6 test types, and each answers a different question. No single test covers both irritation and sensitisation, because the two mechanisms differ.

Irritation peaks fast and fades. Sensitisation appears late, spreads past the chamber boundary and lasts. A program that runs only a closed patch test leaves the sensitisation claim unproven.

The screening tier runs without animals in most markets. OECD Guideline 442C covers protein binding through the Direct Peptide Reactivity Assay, 442D covers keratinocyte activation and 442E covers dendritic cell activation through h-CLAT. Guideline 497 turns those results into fixed interpretation rules.

Test in a pediatric patch test protocol	What it answers	Panel	Window
In chemico and in vitro battery	Sensitisation hazard on raw materials	No human subjects	2 to 4 weeks per assay set
Closed patch test	Acute irritation under occlusion	30 subjects or more	24 hours of wear, read at 30 minutes, 24 and 48 hours
Cumulative irritation test	Irritation from repeated contact	10 to 30 subjects	14 daily applications, about 23 hours each
HRIPT	Sensitisation after repeated exposure	50 to 200 subjects	9 patches, 3 weeks, rest 10 to 14 days, challenge read at 48 to 96 hours
ROAT	Tolerance in real use	10 subjects	5 days of open application, inner elbow
28 day use test	Tolerance in normal use	30 to 120 subjects	4 weeks

How Is a Closed Patch Test Run Step by Step?

A pediatric patch test protocol runs the closed patch test in 6 steps, and the dose is the one buyers skip.

China revised its Human Skin Patch Test Method under NMPA Announcement No. 5 of 2026, effective 1 July 2026. It replaced the method carried in the 2015 Technical Standard. The same announcement revised the Human Safety Use Test Method and added a local lymph node assay.

The revised method fixes the loading. A chamber of about 50 mm2 area and 1 mm depth takes 0.020 to 0.025 g or mL. An undiluted product gets a blank control well, and a diluted product gets its own diluent. The chamber then sits on the upper back or the flexor forearm for 24 hours.

The European convention is tighter on geometry. An 8 mm Finn Chamber takes 20 mg of a petrolatum preparation, near 40 mg per cm2, or 15 microlitres of an aqueous one on filter paper. Chambers stay at least 15 mm apart, which stops one reaction bleeding into the next reading.

Step	Action	What decides the result
1	Consent and screening	No steroid or antihistamine in the days before
2	Skin check	No scar, pigmentation or active lesion
3	Loading the chamber	0.020 to 0.025 g or mL, no rim overflow
4	Application	Upper back or flexor forearm, pressed flat
5	Occlusion	24 hours, no washing, sport or sun
6	Removal and reads	30 minutes, 24 and 48 hours, day 3 or 4, day 7

How Do You Read and Grade the Reactions?

A pediatric patch test protocol uses 2 grading scales, and the challenge reading decides sensitisation. Induction readings track cumulative irritation. Challenge readings track an immune response on a fresh site.

The induction phase uses the Draize scale. Erythema, dryness and wrinkling score from 0 to 4, and oedema scores from 0 to 4 on a separate axis. Those scores feed a mean cumulative irritation index with fixed bands. Below 0.25 is non-irritating, 0.25 to 0.50 very slightly irritating, 0.50 to 1.00 slightly irritating, 1.00 to 2.00 moderately irritating. At 2.00 or above the product irritates.

The challenge phase uses the ICDRG scale. The bands run from negative through doubtful, weak, strong and extreme. An irritant reaction is recorded as Ir, because it does not repeat the immune pathway.

China's revised method uses a 5 band table. Score 0 is negative. Score 1 is doubtful, with faint erythema only. Score 2 is a weak positive with erythema, infiltration, oedema and possible papules. Score 3 is a strong positive with vesicles that may extend past the test site. Score 4 is an extreme positive with confluent vesicles.

Scale	Used at	Bands	What marks sensitisation
Draize	Induction readings	0 to 4 for erythema, 0 to 4 for oedema	Scores build, then settle at rest
Mean cumulative irritation index	Summed induction readings	Under 0.25 up to 2.00 and above	A high index points to irritation, not allergy
ICDRG	Challenge readings	Negative, doubtful, weak, strong, extreme	A reaction that grows between 48 and 72 hours
China 5 band table	Every reading	Scores 0 to 4	Scores 3 and 4 often extend past the site

Timing separates the two mechanisms. An irritant reaction peaks on removal and fades by 48 hours. A sensitised reaction appears or intensifies between 48 and 72 hours, and it can cross the chamber boundary. That is why the protocol keeps a day 7 read.

What Counts as a Pass in Each Market?

A pediatric patch test protocol answers to 1 pass mark per market. China sets the strictest of the 3 markets here.

A sunscreen for children in China must run a closed patch test under the Technical Standard. Among 30 subjects, no more than 1 may show a grade 1 reaction. No subject may show grade 2 or above. The general cosmetic criterion is looser: more than 5 grade 1 reactions or more than 2 grade 2 reactions fails the test.

China also fixes the toxicology gates. Eye irritation must come back non-irritating or minimally irritating, and only a non-irritating result supports a tear-free claim. Skin irritation must be non-irritating, sensitisation must be absent and phototoxicity must not appear.

The age split changes the claim list. Products for infants up to age 3 may claim 6 functions: cleaning, moisturising, hair care, sunscreen, soothing and refreshing. Products for children from 3 to 12 may claim 10 functions, which adds makeup removal, beautifying, fragrance and repair.

Market	Pass mark on the panel	Where the evidence lives	Age rule
China	30 subjects, at most 1 grade 1 reaction, no grade 2 or above	Registration or filing dossier	Infants to age 3 hold 6 claims, children 3 to 12 hold 10
EU	Article 20 of Regulation (EC) No 1223/2009 plus 6 common criteria under Regulation (EU) No 655/2013	Product information file under Article 11	No children's category, so the study must match the target user
US	Section 5 of the FTC Act and the competent and reliable evidence standard	MoCRA safety substantiation and adverse event records	No children's category and no FDA definition

How Do You Bridge an Adult Panel to a Child Claim?

The pediatric patch test protocol bridges to a child claim through 3 links, and a safety assessor signs each one. Without them the file proves tolerance in adults only.

The first link is the age band. ICH E11(R1) sets 5 bands: preterm newborn, term newborn from 0 to 27 days, infants and toddlers from 28 days to 23 months, children from 2 to 11 years, and adolescents. The protocol names the band the product serves.

The second link is exposure. The SCCS Notes of Guidance, 12th revision, carries children's exposure by product category and age. That document is SCCS/1647/22, adopted on 15 May 2023, and it turns an adult panel result into a child exposure argument.

The third link is the formula. The tested sample has to equal the shipped product, and batch records close that gap. A study on a pilot batch proves little once the preservative system moves.

China adds a fourth demand through post-market monitoring. During the monitoring period, the registrant files adverse reaction data from Chinese child consumers, covering sales volume and case summaries.

Which Documents Turn the Protocol Into Evidence?

A pediatric patch test protocol becomes evidence only when 7 documents hold together. Any one of them missing turns the claim into marketing copy.

The report carries 8 fields under the EU Technical Document on Cosmetic Claims: product identification, objective, schedule, protocol, results, interpretation, statistics and the signature of the person in charge. Product identification links the tested sample to the product on the shelf.

Document	What a buyer reads for	Who holds it
Dated study protocol	Objective, panel, criteria, readings, endpoints	Testing laboratory
Ethics statement and consent form	Informed consent under the Declaration of Helsinki	Testing laboratory
Supervising dermatologist record	Board certification and role, for the file only	Testing laboratory
Adverse event log	Every reaction and the action taken	Testing laboratory
Final signed report	Results, interpretation, statistics, sign-off	Testing laboratory
Batch and process records	Proof that the tested formula shipped	Manufacturer
Bridging rationale and safety assessment	Why an adult panel covers the child claim	Safety assessor

What Does DEVA Skincare Bring to a Pediatric Patch Test Protocol?

DEVA Skincare has run 20 years of baby and sensitive skin programs, with 150 protocols on the bench. Those protocols cover cell efficacy and toxicity, the chorioallantoic membrane irritation assay, melanin inhibition and preservative challenge.

Six laboratories carry the work. Product efficacy evaluation uses VISIA imaging across 12 skin indicators. Active analysis runs on HPLC, GC and UV-Vis. Other benches cover extraction, fermentation, packaging ageing and heavy metals, and every batch clears 72 process control steps.

Production runs in a 100,000 grade GMPC cleanroom, and the core laboratories are built to CNAS standards. DEVA holds 70 or more granted patents, plus 22 special cosmetics certificates and 21 more under application. Four factories carry 20 million units of monthly capacity.

The schedule is fixed. Sampling takes 1 week. Mass production starts 6 weeks after sample approval, and each test protocol runs about 4 weeks. Standard MOQ is 5,000 units per SKU, 10,000 for aluminium cans, 50,000 for masks and 200,000 for ampoules.

Send the target market, the age band and the pack format through the inquiry form on this page. We will turn the brief into a pediatric patch test protocol with a named subject band, a reading schedule and a pass mark for your market. Baby lotion, wash and sunscreen briefs start the same way.

How many subjects does a closed patch test need?

China's revised method requires at least 30 subjects who complete the test. An HRIPT runs on 50 to 200 subjects, because sensitisation is a low-frequency event. A 28 day use test covers 30 to 120 subjects. Panel size follows the endpoint, not the budget.

Can a pediatric patch test protocol use child volunteers?

No. China's Children's Cosmetics Technical Guidance Principles rule out clinical trials on children, and no other market runs a controlled patch test on infants for a claim file. The evidence comes from an adult panel, in vitro screening and post-market adverse reaction monitoring on child consumers.

What is the difference between a closed patch test and an HRIPT?

A closed patch test applies the product once under 24 hours of occlusion and reads acute irritation. An HRIPT applies 9 patches over 3 weeks, rests for 10 to 14 days, then re-challenges a naive site to detect sensitisation. One measures irritation, the other sensitisation.

How long does a pediatric patch test protocol take?

Plan about 4 weeks per protocol, with most protocols running side by side. An HRIPT alone needs 3 weeks of induction, a 10 to 14 day rest and a challenge read at 48 to 96 hours. Sampling takes 1 week, and mass production starts 6 weeks after sample approval.

What dose and chamber does the protocol use?

China's method specifies a chamber of about 50 mm2 area and 1 mm depth, loaded with 0.020 to 0.025 g or mL. The European convention uses an 8 mm Finn Chamber, loaded with 20 mg of a petrolatum preparation or 15 microlitres of an aqueous one on filter paper.

Is a patch test enough to support a pediatric dermatologist tested claim?

No. A patch test measures irritation and sensitisation on the tested sample. The claim also needs a supervising dermatologist, a report with 8 fields and a bridging rationale that ties the sample to the marketed product. That is what a pediatric patch test protocol has to deliver.